Podcast Episodes
Back to Search
Challenging Research Models to Improve Health Equity
Diversity, equity and inclusion (DEI) continues to be a challenge for drug and medical device developers. While there has been some improvement in cl…
2 years ago
BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More
We’re off to a rocky start this week on the clinical side, with some safety issues. BioNTech and MediLink’s ADC was placed on partial hold after mult…
2 years ago
BioSpace at #DIA2024: Convergence and Collaboration
BioSpace's Lori Ellis and Chantal Dresner are bringing live updates from #DIA2024 in San Diego this week where the first day kicked off with an inspi…
2 years ago
Donanemab’s Promise, BIO Wrap and Mass Layoffs
The big news of this week so far was Monday’s FDA advisory committee for Eli Lilly’s Alzheimer’s drug donanemab, where the vote was unanimous in supp…
2 years ago
BioSpace x DIA: Robust Integrated Regulatory Strategies
How do we ensure strategic vision and thoughtful implementation when pursuing new opportunities in science and technology?
Our guests discuss challen…
2 years, 1 month ago
The ABCs of Biopharma This Week: ASCO, BIO and Cancer
Conference season kicked into high gear this week with the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and the BIO Interna…
2 years, 1 month ago
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion
Regulators suggest developers engage in discussions early, however those conversations cannot take place unless developers are sure of the asset's ca…
2 years, 1 month ago
AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO
At its Investor Day 2024 event last week, AstraZeneca announced plans to reach $80 billion in total revenue by 2030—up from $45.8 billion in 2023—and…
2 years, 1 month ago
BioSpace x DIA: Navigating the Emergence of CGT Combination Products
With every new advancement in either science or technology there is increased excitement as we see the potential. Cell and gene therapies (CGT) as co…
2 years, 1 month ago
Bayer’s New Strategy, Novo Vs. Lilly and Psychedelics
Bayer’s recent layoffs of 1,500 mark a step toward CEO Bill Anderson’s stated goal of removing managerial layers at the company—“fewer bosses, fewer …
2 years, 1 month ago